Scully v. AltaThera Pharmaceuticals LLC

2025 IL App (1st) 242078-U
CourtAppellate Court of Illinois
DecidedJune 30, 2025
Docket1-24-2078
StatusUnpublished

This text of 2025 IL App (1st) 242078-U (Scully v. AltaThera Pharmaceuticals LLC) is published on Counsel Stack Legal Research, covering Appellate Court of Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Scully v. AltaThera Pharmaceuticals LLC, 2025 IL App (1st) 242078-U (Ill. Ct. App. 2025).

Opinion

2025 IL App (1st) 242078-U No. 1-24-2078 Order filed June 30, 2025. First Division

NOTICE: This order was filed under Supreme Court Rule 23 and is not precedent except in the limited circumstances allowed under Rule 23(e)(1). ______________________________________________________________________________ IN THE APPELLATE COURT OF ILLINOIS FIRST DISTRICT ______________________________________________________________________________ JAMES SCULLY, ) Appeal from the ) Circuit Court of Plaintiff-Appellant, ) Cook County. ) v. ) No. 22 L 11440 ) ALTATHERA PHARMACEUTICALS LLC, ) The Honorable ) Catherine A. Schneider, Defendant-Appellee. ) Judge Presiding.

JUSTICE LAVIN delivered the judgment of the court. Presiding Justice Fitzgerald Smith and Justice Pucinski concurred in the judgment.

ORDER

¶1 Held: Appeal dismissed for lack of jurisdiction where the circuit court’s dismissal of two counts in plaintiff’s second amended complaint did not constitute a final judgment.

¶2 Plaintiff James Scully filed suit against defendant AltaThera, setting forth a number of

counts seeking relief for violations under the Illinois Wage Payment and Collection Act (Wage

Act) (820 ILCS 115/1 et seq. (West 2022)), breach of contract, and quantum meruit. The circuit

court eventually dismissed the Wage Act and breach of contract counts with prejudice, but allowed No. 1-24-2078

Scully to proceed on the quantum meruit counts. Scully filed an amended complaint only alleging

the quantum meruit counts and later sought a finding, pursuant to Illinois Supreme Court Rule

304(a) (eff. Mar. 8, 2016), that the dismissal of the Wage Act and breach of contract counts was a

final, appealable judgment. The court granted Scully’s request, and he appealed.

¶3 AltaThera now asserts the lower court’s Rule 304(a) finding was improper because the

dismissal of Scully’s Wage Act and breach of contract counts was not a final judgment, since those

counts contained the same operative facts as Scully’s quantum meruit counts that are still pending

in the court below. We agree. For the following reasons, we dismiss the appeal for lack of

jurisdiction.

¶4 I. BACKGROUND

¶5 On December 27, 2024, Scully filed a complaint alleging that AtlaThera failed to fully

compensate him for work performed from December 1, 2018, through October 10, 2021, when he

worked as AltaThera’s full-time Chief Financial Officer (CFO), a fact that AtlaThera later denied

in its answer. AltaThera successfully moved to dismiss the complaint pursuant to section 2-615 of

the Code. The court dismissed the complaint without prejudice and granted Scully leave to amend

his pleadings. Scully filed a first amended complaint, but then moved for leave to file a second

amended complaint, which the court allowed.

¶6 Scully’s second amended complaint set forth five counts, all seeking compensation for his

alleged work as AltaThera’s CFO: (1) compensation owed under the Wage Act; (2) breach of

contract; (3) quantum meruit relief for compensation excluding equity; (4) quantum meruit relief

for an equity stake; and (5) reimbursement for the employer share of payroll taxes paid by Scully.

-2- No. 1-24-2078

¶7 Scully alleged that he worked as AltaThera’s full-time CFO from about December 1, 2018,

to October 10, 2021. He worked for “at least” 40 hours a week and “usually” more than 40 hours.

In early January 2019, he and AltaThera’s Chief Executive Officer entered into a verbal agreement

regarding compensation by AltaThera for Scully’s work, effective as of December 1, 2018. Their

agreement called for Scully to bill AltaThera for 32 hours of work a week in exchange for $25,000

a month, which equated to an hourly rate of about $180. Scully alleged that “[t]his verbal

agreement did not address the situation where [he] worked more than 32 hours per week.”

Nonetheless, according to Scully, AltaThera knowingly allowed him to work 40 or more hours a

week and “accepted all of the work Scully performed.” From September 2019 through February

2021, AltaThera allegedly initiated an “austerity program” whereby it paid Scully for less than 32

hours a week, regardless of how many hours Scully worked. Scully also claimed that, from March

2021 through October 2021, AltaThera paid him a temporary rate of $18,750 a month while

negotiating an employment contract with him. Scully alleged that he resigned from his position as

“full-time CFO of AltaThera,” effective October 11, 2021.

¶8 In his Wage Act count, Scully alleged that, as an “employee” of AltaThera under the Wage

Act, he was owed $327,047.69 in wages for the unpaid work he performed from December 2018

through October 10, 2021, i.e., the hours of work exceeding 32 hours a week. He also alleged he

was entitled to compensation for the reductions in pay AltaThera made during the alleged

“austerity program” and employment contract negotiations. In his breach of contract count, Scully

alleged that he and AltaThera entered into a contract, which AltaThera breached by not paying

him the agreed hourly rate of $180.29 for each hour he worked.

-3- No. 1-24-2078

¶9 AltaThera moved to dismiss Scully’s second amended complaint pursuant to section 2-615

of the Code. On December 8, 2023, after briefing on the motion, the circuit court granted

AltaThera’s dismissal motion. The court dismissed with prejudice Scully’s Wage Act, breach of

contract, and tax counts. It found in part that Scully failed to allege that AltaThera agreed to pay

him for more than 32 hours of work a week. The court also dismissed Scully’s two quantum meruit

counts without prejudice, allowing Scully leave to amend them.

¶ 10 On January 8, 2024, Scully moved to reconsider the court’s dismissal. On May 2, 2024,

the court denied the motion as to Scully’s Wage Act, breach of contract, and tax counts, but granted

the motion as to his quantum meruit counts.

¶ 11 On May 9, 2024, Scully filed a third amended complaint, restating his two quantum meruit

counts but omitting all other counts alleged in the second amended complaint. He again stated the

facts in his second amended complaint regarding his work provided as a “full-time CFO” for

AltaThera from December 1, 2018, through October 10, 2021. For his first quantum meruit count,

Scully alleged he was entitled to compensation for “non-gratuitously performed services” as CFO

to AltaThera’s benefit, which AltaThera accepted. He sought $326,952 in damages, calculated by

multiplying a $180 hourly rate by the amount of hours worked without compensation. For his

second quantum meruit count, Scully alleged that he was also entitled to $406,233, the alleged fair

cash value of an equity stake in AltaThera that he claimed was owed to him.

¶ 12 On May 31, 2024, while Scully’s third amended complaint was pending, Scully filed a

notice of appeal. We dismissed the appeal for lack of jurisdiction. Scully v. AltaThera

Pharmaceuticals, No. 1-24-1182 (Aug. 9, 2024) (dispositional order dismissing the appeal for lack

-4- No. 1-24-2078

of this court’s jurisdiction). In the meantime, AltaThera had filed an answer to Scully’s third

amended complaint.

¶ 13 On July 30, 2024, Scully moved for a Rule 304(a) finding there was no just reason for

delaying either enforcement or appeal or both of the circuit court’s dismissal of his second

amended complaint’s Wage Act and breach of contract counts. AltaThera filed a response, arguing

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cano v. Cruz
Appellate Court of Illinois, 2026

Cite This Page — Counsel Stack

Bluebook (online)
2025 IL App (1st) 242078-U, Counsel Stack Legal Research, https://law.counselstack.com/opinion/scully-v-altathera-pharmaceuticals-llc-illappct-2025.